José Miguel Torregrosa Diaz

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation

Pilar Gallego, Vanessa Roldán, José Miguel Torregrosa Diaz et al. · Circulation Arrhythmia and Electrophysiology · 2012 · 147 citations

Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients

Vanessa Roldán, Begoña Muiña, José Miguel Torregrosa Diaz et al. · Journal of the American College of Cardiology · 2011 · 130 citations

Thrombosis, Venous Thrombosis, Cardiovascular Disease +13

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

Raphaël Itzykson, Valeria Santini, Sylvain Thépot et al. · Journal of Clinical Oncology · 2022 · 40 citations · Full text

Low‐dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment‐free remission in chronic myeloid leukemia patients: Results of a retrospective study

Émilie Cayssials, José Miguel Torregrosa Diaz, Pilar Gallego‐Hernanz et al. · Cancer · 2020 · 29 citations